Glucagon-like peptide 1 agonists in cardio-oncology: is it time for a specific focus? - Takeaways - MDSpire

Glucagon-like peptide 1 agonists in cardio-oncology: is it time for a specific focus?

  • By

  • Teresa López-Fernández

  • Pietro Ameri

  • February 8, 2025

  • 0 min

Share

  • 1

    Multiple myeloma (MM) is a heterogeneous disease primarily affecting older adults, with significant cardiovascular risks associated with its treatment.

  • 2

    Glucagon-like peptide 1 agonists (GLP1a) show promise in improving cardiovascular outcomes and may have antitumoural effects in patients with MM.

  • 3

    A study found that GLP1a use in MM patients with Type 2 diabetes was linked to a 33% lower risk of major adverse cardiovascular events.

  • 4

    GLP1a therapy was associated with a 44% reduction in mortality among MM patients, suggesting potential cardioprotective benefits.

  • 5

    Further research is needed to confirm GLP1a's effects on MM and its cost-effectiveness in preventing cardiovascular complications.

Original Source(s)

Glucagon-like peptide 1 agonists in cardio-oncology: is it time for a specific focus?

  • by Teresa López-Fernández, Pietro Ameri

  • February 8, 2025

Related Content

Quantitative CT assessment of intrathoracic visceral fat depots and their association with incident heart failure in asymptomatic adults

Prognostic value of CTI for major adverse cardiovascular events in patients With ST-elevation myocardial infarction after primary percutaneous coronary intervention

Transcriptomic signatures and immune microenvironment of acute rejection after heart transplantation: an integrated bioinformatics analysis